A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers

Anderson, Doug; Shelley, Sarah; Crick, N; Buraglio, Mauro

doi:10.5414/cpp40457

Cited by 14 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of drug interaction in this study is in agreement with the results of previous studies with other CYP2C9 substrates such as diclofenac 14 and warfarin 12 , in which the pharmacokinetics of either drug were unchanged upon coadministration.…”

Section: Discussionsupporting

confidence: 92%

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol

Sunkara

Bigler

Smith

et al. 2004

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol

Sunkara

Bigler

Smith

et al. 2004

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Previous studies into CYP suggest the involvement of the isozymes CYP2C9 and CYP3A4 in nateglinide metabolism, 8 although nateglinide did not show any interaction with diclofenac. 13 The isozyme CYP2C9 is also primarily responsible for the metabolism of the more potent S-enantiomer of warfarin. Therefore, nateglinide may have the potential to compete with warfarin for this metabolic pathway.…”

Section: Discussionmentioning

confidence: 99%

No Effect of the Novel Antidiabetic Agent Nateglinide on the Pharmacokinetics and Anticoagulant Properties of Warfarin in Healthy Volunteers

Anderson¹,

Shelley²,

Crick³

et al. 2002

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The novel hypoglycemic agent nateglinide is pharmacologically distinct from oral hypoglycemic agents such as sulfonylureas and repaglinide. The present study investigated the effects in healthy volunteers of multiple doses of nateglinide on the pharmacokinetics and pharmacodynamics of warfarin. The study comprised a randomized two-group, two-way crossover, open-label design in 12 healthy male subjects. One group of 6 subjects initially received a single oral dose of warfarin 30 mg and then, after a 7- to 14-day washout, received both warfarin and nateglinide (120 mgnateglinide, 10 min before meals for 4 days and a single dose of 30 mg warfarin on the second day). The alternate group of 6 subjects received treatments in the opposite order. Pharmacokinetic profiles were derived from plasma warfarin and nateglinide concentrations. Prothrombin measurements were evaluated in both periods as a measure of warfarin activity. When administered alone or in combination, there were no statistically significant differences in mean warfarin (R- and S-enantiomers) or nateglinide pharmacokinetic parameters. The concurrent administration of nateglinide and warfarin did not affect the maximal change in prothrombin time that follows warfarin administration. In this study, there was no evidence of an effect of coadministration of nateglinide on the pharmacodynamic action of warfarin or any pharmacokinetic interaction between warfarin and nateglinide.

show abstract

“…The enzymes involved in the metabolism of nateglinide have not yet been fully characterized, but in vitro studies suggest that CYP2C9 and CYP3A4 participate in its biotransformation 8 , 9 . In one study the CYP2C9 substrate diclofenac 10 had no significant effect on the pharmacokinetics of nateglinide 11 . However, there are no published studies on the interactions of nateglinide with potent inhibitors of CYP2C9.…”

mentioning

confidence: 99%

Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

Niemi

Neuvonen

Juntti‐Patinen

et al. 2003

Clinical Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers

Cited by 14 publications

References 0 publications

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol

The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol

No Effect of the Novel Antidiabetic Agent Nateglinide on the Pharmacokinetics and Anticoagulant Properties of Warfarin in Healthy Volunteers

Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

Contact Info

Product

Resources

About